Chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
5 microgram once daily tiotropium
5 microgram once daily tiotropium and 150 microgram once daily indacaterol
Sponsors
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient who is outpatient of Chiba-Hokusoh Hospital is able to read and understand the Informed Consent Form and he/she will sign the Informed Consent. 2. COPD patient, over 40 years, meets all of the following inclusion criteria. Current or former smokers. FEV1/FVC level is within 70% after 15 minutes used the bate 2 agonist on respiratory function test .
Exclusion criteria
Exclusion criteria: 1. Patient who has an anamnesis of hypersensitivity to the medicine used by this research . 2. Patient of the symptom that bronchial asthma is main. 3. Patient who has already used LABA other than indacaterol. The patient who is using other LABA presupposes that participation is possible, when the wash out period for four weeks or more is prepared before a start. 4. A glaucomatous patient 5. Patient with the urination trouble by prostatic hypertrophy. 6. Patient who was considered ineligible by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1(The add-on effects of the combined therapy on FEV1 in patients with COPD. 2) CAT (COPD Assessment Test) score and modified medical research council score | — |
Secondary
| Measure | Time frame |
|---|---|
| Airway resistance (R5, R20, R5-R20) Change of HADS (Hospital Anxiety and Depression Scale) Change of Rint (Interrupter airway resistance) Safety | — |
Countries
Japan
Contacts
Public ContactYosuke Tanaka
Chiba-Hokusoh Hospital, Nippon Medical School Department of Respiratory Medicine
Outcome results
None listed